Jiangsu Hengrui Pharmaceuticals Co.,Ltd (SHA:600276)
China · Delayed Price · Currency is CNY 48.46
-0.16 (-0.33%)
Oct 30, 2026, 3:00 PM CST
SHA:600276 Revenue
Jiangsu Hengrui Pharmaceuticals Co.,Ltd had revenue of 7.32B CNY in the quarter ending June 30, 2026, a decrease of -14.50%. This brings the company's total for the last twelve months to 32.85B, up 6.02% year-over-year. In the year 2025, Jiangsu Hengrui Pharmaceuticals Co.,Ltd had annual revenue of 31.63B with 13.02% growth. That makes Jiangsu Hengrui Pharmaceuticals Co.,Ltd the 2,658th largest company in the world by revenue and 301st in China.
Revenue (ttm)
32.85B
Revenue Growth
+6.02%
P/S Ratio
9.72
Revenue / Employee
1.59M
Employees
20,602
Market Cap
319.38B
Revenue by Geography
- China 26.86B 84.9%
- Foreign 4.77B 15.1%
Fiscal year ended Dec 31, 2025 See the full SHA:600276 breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 31.63B | 3.64B | 13.02% |
| Dec 31, 2024 | 27.98B | 5.16B | 22.63% |
| Dec 31, 2023 | 22.82B | 1.54B | 7.26% |
| Dec 31, 2022 | 21.28B | -4.63B | -17.87% |
| Dec 31, 2021 | 25.91B | -1.83B | -6.59% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Huadong Medicine | 43.97B |
| Yunnan Baiyao Group Co.,Ltd | 42.79B |
| Shanghai Fosun Pharmaceutical (Group) | 42.73B |
| China Resources Sanjiu Medical & Pharmaceutical | 31.03B |
| Zhejiang NHU Company | 24.84B |
| Humanwell Healthcare (Group) | 23.96B |
| Beijing Tongrentang | 15.87B |
| Changchun High-Tech Industry (Group) | 10.53B |
Jiangsu Hengrui Pharmaceuticals Co.,Ltd News
- 4 days ago - Jiangsu Hengrui Pharmaceuticals Co.,Ltd Quarterly report: Q3 2026 - Filings
- 2 months ago - Jiangsu Hengrui Pharmaceuticals Co.,Ltd Quarterly report: H1 2026 - Filings
- 3 months ago - Chinese drugmakers with big ambitions struggle to recruit staff for global expansion - Reuters
- 6 months ago - Jiangsu Hengrui Pharmaceuticals Co.,Ltd Quarterly report: Q1 2026 - Filings
- 7 months ago - Jiangsu Hengrui Pharmaceuticals Co.,Ltd Annual report: H2 2025 - Filings